Premature ventricular contraction laboratory findings
|
Premature ventricular contraction Microchapters |
|
Differentiating Premature Ventricular Contraction from other Disorders |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Premature ventricular contraction laboratory findings On the Web |
|
FDA on Premature ventricular contraction laboratory findings |
|
Premature ventricular contraction laboratory findings in the news |
|
Blogs on Premature ventricular contraction laboratory findings |
|
to Hospitals Treating Premature ventricular contraction laboratory findings |
|
Risk calculators and risk factors for Premature ventricular contraction laboratory findings |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Radwa AbdElHaras Mohamed AbouZaied, M.B.B.S[2] Homa Najafi, M.D.[3] Mugilan Poongkunran M.B.B.S [4]
Overview
Many cases of premature ventricular contraction have no definite cause, it may be the result of various other problems. If PVC patients present with symptoms, a generalized approach is done to find the precipitating factors.
Laboratory Findings
The following investigations are done to patients with symptoms :
- Renal function and electrolytes
- Complete blood count
- ABG : To rule out hypercapnia and hypoxia.
- Thyroid-stimulating hormone : To rule out hyperthyroidism and of relevance if amiodarone is administered for treatment.
2017 AHA/ACC/HRS Guideline for Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death (DO NOT EDIT)[1]
Recommendation for Biomarkers
| Class IIa |
| 1. In patients with structural heart disease, measurement of natriuretic peptides (BNP or N-terminal pro-BNP) can be useful by adding prognostic information to standard risk factors for predicting SCD or SCA (Level of Evidence: B-NR).[2][3][4][5] |
Recommendation for Genetic Counselling
| Class I |
| 1. In patients and family members in whom genetic testing for risk stratification for SCA or SCD is recommended, genetic counseling
is beneficial. (Level of Evidence: C-EO). |
References
- ↑ Al-Khatib, Sana M.; Stevenson, William G.; Ackerman, Michael J.; Bryant, William J.; Callans, David J.; Curtis, Anne B.; Deal, Barbara J.; Dickfeld, Timm; Field, Michael E.; Fonarow, Gregg C.; Gillis, Anne M.; Granger, Christopher B.; Hammill, Stephen C.; Hlatky, Mark A.; Joglar, José A.; Kay, G. Neal; Matlock, Daniel D.; Myerburg, Robert J.; Page, Richard L. (2018). "2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death". Circulation. 138 (13). doi:10.1161/CIR.0000000000000549. ISSN 0009-7322.
- ↑ Scott, Paul A.; Barry, James; Roberts, Paul R.; Morgan, John M. (2009). "Brain natriuretic peptide for the prediction of sudden cardiac death and ventricular arrhythmias: a meta-analysis". European Journal of Heart Failure. 11 (10): 958–966. doi:10.1093/eurjhf/hfp123. ISSN 1388-9842.
- ↑ Levine, Yehoshua C.; Rosenberg, Michael A.; Mittleman, Murray; Samuel, Michelle; Methachittiphan, Nilubon; Link, Mark; Josephson, Mark E.; Buxton, Alfred E. (2014). "B-type natriuretic peptide is a major predictor of ventricular tachyarrhythmias". Heart Rhythm. 11 (7): 1109–1116. doi:10.1016/j.hrthm.2014.04.024. ISSN 1547-5271.
- ↑ Berger, Rudolf; Huelsman, Martin; Strecker, Karin; Bojic, Anja; Moser, Petra; Stanek, Brigitte; Pacher, Richard (2002). "B-Type Natriuretic Peptide Predicts Sudden Death in Patients With Chronic Heart Failure". Circulation. 105 (20): 2392–2397. doi:10.1161/01.CIR.0000016642.15031.34. ISSN 0009-7322.
- ↑ Ahmad, Tariq; Fiuzat, Mona; Neely, Benjamin; Neely, Megan L.; Pencina, Michael J.; Kraus, William E.; Zannad, Faiez; Whellan, David J.; Donahue, Mark P.; Piña, Ileana L.; Adams, Kirkwood F.; Kitzman, Dalane W.; O'Connor, Christopher M.; Felker, G. Michael (2014). "Biomarkers of Myocardial Stress and Fibrosis as Predictors of Mode of Death in Patients With Chronic Heart Failure". JACC: Heart Failure. 2 (3): 260–268. doi:10.1016/j.jchf.2013.12.004. ISSN 2213-1779.